Upstream Bio says Phase 2 VIBRANT trial shows verekitug improves nasal polyp score in about 80% of CRSwNP patients
PUBT · 06/14 14:00
Share
Listen to the news
- Upstream Bio presented new post-hoc responder analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps at EAACI 2026.
- Quarterly dosing drove clinically meaningful symptom improvement for most treated participants, supporting a differentiated efficacy profile in severe, inadequately controlled disease.
- Management flagged plans to move into Phase 3 trials in CRSwNP, with a parallel Phase 3 program in severe asthma targeted for Q1 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141000PRIMZONEFULLFEED9746649) on June 14, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending